Intelligent Relations
Preston by Intelligent Relations
Elaine Chen
Gray shield icon
Is this you?
Claim your profile.

Elaine Chen

National Biotech Reporter

AS SEEN ON
STAT News, DIGITIMES Asia, The Boston Globe

Preston's Summary

Elaine Chen is a national biotech reporter at STAT and co-writes The Readout newsletter. She covers a range of topics related to medicine and healthcare, with a focus on pharmaceuticals, public health, and the intersection of AI and healthcare. Elaine's work has been featured in prominent publications including BioRxiv, Yahoo Finance, Bloomberg News, and The New York Times.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

Coverage Attributes:

Beta
Informative: 49 %
Data Driven: 15 %
Interviews Q&as: 11 %
Promotional: 7 %
Opinion: 7 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Pharmaceutical Manufacturing
  • Pharmaceutical Regulation
  • Gene Therapy
  • Immunology
  • Immunotherapy
  • Oncology
  • Pancreatic Cancer Research
  • Mental Health Care

Pitching Insights

Elaine Chen's coverage primarily focuses on healthcare, pharmaceuticals, and to a lesser extent finance. Her articles frequently cite data and press releases. Sources with access to relevant research findings or industry statistics may find success in pitching to her.

Given the prevalence of topics related to obesity, weight-loss drugs, and health research in her articles, Elaine would likely welcome insights from medical professionals specializing in these areas. Additionally, she might be interested in hearing from experts able to provide context around new developments within the pharmaceutical industry.

As Elaine does not have a specific geographic focus mentioned but covers international news across healthcare and finance sectors, she is likely open to receiving pitches from sources located anywhere globally who can offer valuable insights into these industries.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Ben Fidler

Ben Fidler

Senior Editor
******r@*************com
Publications
BioPharma Dive
Most recent topics
Not enough data
Heather McKenzie

Heather McKenzie

Senior Editor
*************zie@**********om
Publications
BioSpace
Most recent topics
Not enough data
Allison Deangelis

Allison Deangelis

Reporter
**************lis@**********om
Publications
STAT News, RamaOnHealthcare, The Boston Globe
Most recent topics
Not enough data
Adam Feuerstein

Adam Feuerstein

Senior Writer, National Biotech Columnist
************ein@**********om
Publications
STAT News, RamaOnHealthcare
Most recent topics
Not enough data
Jonathan Gardner

Jonathan Gardner

Senior Reporter
******er@*************com
Publications
BioPharma Dive, Healthcare Dive
Most recent topics
Not enough data
Gabrielle Masson

Gabrielle Masson

Writer
******n@*********om
Publications
BioSpace
Most recent topics
Not enough data

Articles

STAT News

Amylyx endocrine drug succeeds in pivotal study

Amylyx endocrine drug succeeds in pivotal study

By: Elaine Chen

In a Phase 3 trial of people with post-bariatric hypoglycemia, or PBH, those taking the drug experienced a 55% reduction in the rate of serious low blood sugar events compared with those on placebo. This was better than expected; the study was statistically powered to show a 35% improvement over placebo.

© 2026 Intelligent Relations